N/A
Completed N=8,145
Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov NCT02489942 ↗Enrolled (actual)
8,145
Serious AEs
4.8%
Results posted
Feb 2022
Primary outcomePrimary: Number of Patients With Adverse Drug Reactions (ADRs) — 1029 Participants
Summary
Study to investigate the safety and efficacy of long-term daily use of JARDIANCE® Tablets in Japanese patients with type 2 diabetes mellitus
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients With Adverse Drug Reactions (ADRs) |
1029 | — |
| SECONDARY Change From Baseline in Haemoglobin A1c (HbA1c) at the Last Observation During the Observation Period |
-0.74 | — |
| SECONDARY Change From Baseline in Fasting Plasma Glucose (FPG) at the Last- Observation During Observation Period |
-30.1 | — |
Eligibility Criteria
Inclusion criteria
Male and female Japanese patients with type 2 diabetes mellitus who have never been treated with JARDIANCE® Tablets before the enrolment
Exclusion criteria
None
Data sourced from ClinicalTrials.gov (NCT02489942). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.